https://www.yiliao.com/index.php?action=history&feed=atom&title=%E8%82%BF%E7%98%A4%E5%9D%8F%E6%AD%BB%E5%9B%A0%E5%AD%90%E5%8F%97%E4%BD%931
肿瘤坏死因子受体1 - 版本历史
2026-04-06T13:44:41Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E8%82%BF%E7%98%A4%E5%9D%8F%E6%AD%BB%E5%9B%A0%E5%AD%90%E5%8F%97%E4%BD%931&diff=313170&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T02:49:28Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[肿瘤坏死因子受体1]]([[TNFR1]])</strong>，官方基因命名为<strong>[[TNFRSF1A]]</strong>，又称<strong>[[p55]]</strong>或<strong>[[CD120a]]</strong>，是一种在人体绝大多数细胞中广泛表达的跨膜受体。作为<strong>[[肿瘤坏死因子受体超家族]]([[TNFRSF]])</strong>的关键成员，[[TNFR1]]胞内段特有的<strong>[[死亡结构域]]([[DD]])</strong>使其具备了介导细胞凋亡、程序性坏死及全身促炎反应的能力。在2026年的精准医学研究中，[[TNFR1]]不仅是<strong>[[TRAPS综合征]]</strong>的致病核心，其受体脱落机制的异常也被确认为介导<strong>[[细胞因子风暴]]</strong>及慢性神经炎症的关键开关。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">TNFR1</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">TNFRSF1A (CD120a)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Receptor Structure: Extracellular CRDs-TM-DD</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">基因标志：[[TNFRSF1A]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7132</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">11916</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P19438</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约55kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键基序</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[死亡结构域]]([[DD]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">中国医保</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">靶向单抗入保([[NRDL]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">自身炎症疾病精准靶点</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：信号通路的“二分决策”</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[TNFR1]]是典型的多效性受体，其下游信号根据细胞微环境分为两条截然不同的路径：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>复合体I(促炎与存活)：</strong><br />
当[[TNF-α]]结合[[TNFR1]]后，受体在胞质端迅速召集适配蛋白<strong>[[TRADD]]</strong>、[[RIPK1]]和[[TRAF2]]。这一过程激活了<strong>[[NF-κB]]</strong>通路，诱导大量细胞因子产生，促进细胞在炎症环境下的存活。</li><br />
<li style="margin-bottom: 12px;"><strong>复合体II(程序性死亡)：</strong><br />
若NF-κB信号受阻或受体发生胞吞内化，[[RIPK1]]转而招募<strong>[[FADD]]</strong>和[[Caspase-8]]。这一转变启动<strong>[[细胞凋亡]]</strong>链条；若Caspase-8活性缺失，细胞则进入<strong>[[程序性坏死]]</strong>(Necroptosis)，引发更剧烈的炎症。</li><br />
<li style="margin-bottom: 12px;"><strong>受体脱落(Shedding)：</strong><br />
金属蛋白酶<strong>[[ADAM17]]</strong>(TACE)可剪切受体胞外域，释放可溶性[[TNFR1]]([[sTNFR1]])。2026年的分子诊断标准将其作为预测<strong>[[ARDS]]</strong>患者病死率的独立生物指标。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026临床关联与病理表现</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 30%;">病理类型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">[[TNFR1]]异常机制(2026)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床意义</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[TRAPS综合征]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">基因突变导致受体无法正常脱落，在内质网蓄积。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">自发性<strong>[[周期性发热]]</strong>，需精准基因测序。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[重症脓毒症]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">受体脱落过度导致[[sTNFR1]]作为“分子海绵”耗尽。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">监测<strong>[[炎症风暴]]</strong>状态，指导类固醇精准给药。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[多发性硬化症]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">受体介导的小胶质细胞促炎极化。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[TNFR1拮抗抗体]]</strong>临床试验重点领域。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：从广谱抑制向亚型靶向进化</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
针对[[TNFR1]]的临床干预在2026年已实现由“全阻断”向“亚型定向调控”的跨越：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>亚型选择性阻断：</strong>传统抑制剂如[[英夫利昔单抗]]同时影响TNFR1和TNFR2。2026年新研发出的<strong>[[TNFR1拮抗剂]]</strong>旨在仅阻断TNFR1介导的促炎信号，而保留<strong>[[TNFR2]]</strong>介导的组织修复和神经保护功能，显著降低了感染风险。</li><br />
<li style="margin-bottom: 12px;"><strong>TRAPS 的靶向替代：</strong>由于TRAPS患者对受体阻断反应不一，2026年专家共识推荐在[[TNFR1]]突变类型明确的情况下，首选<strong>[[IL-1抑制剂]]</strong>作为下游阻断策略。</li><br />
<li style="margin-bottom: 12px;"><strong>sTNFR1监测驱动治疗：</strong>在2026版ICU标准化路径中，动态监测[[sTNFR1]]水平已被用于指导<strong>[[细胞因子吸附柱]]</strong>的启用时机。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[死亡结构域]]([[DD]])：</strong>触发程序性细胞死亡信号链的关键结构基序。</li><br />
<li style="margin-bottom: 8px;"><strong>[[TNFR2]]([[TNFRSF1B]])：</strong>缺乏[[DD]]，主要介导免疫自稳与修复，常作为[[TNFR1]]的功能对手。</li><br />
<li style="margin-bottom: 8px;"><strong>[[TRADD]]：</strong>[[TNFR1]]胞内信号转导的第一顺位适配蛋白。</li><br />
<li style="margin-bottom: 8px;"><strong>[[ADAM17]]：</strong>又称[[TACE]]，负责调控受体从细胞表面“剥离”进入血液。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Wajant H,et al.(2023/2025Revision).</strong> <em>Molecular mechanisms of TNFR1 signaling in inflammation and cell death.</em> <strong>[[The Journal of Clinical Investigation]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：该项深度解析明确了复合体I与II转换的动力学模型，为2026年开发新型抗炎药提供了理论框架。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[EULAR]]Autoinflammatory Working Group(2026).</strong> <em>Management of TNFRSF1A-associated periodic syndrome:2026 updated guidelines.</em> <strong>[[Annals of the Rheumatic Diseases]]</strong>.<br><br />
<span style="color: #475569;">[学术点评]：最新的治疗指南强调了基于基因突变位点的风险分层管理在TRAPS患者中的核心价值。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
TNFR1 (TNFRSF1A) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联配体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[TNF]] • [[TNF-α]] • [[淋巴毒素-α]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">信号分子</td><br />
<td style="padding: 10px 15px; color: #334155;">[[TRADD]] • [[RIPK1]] • [[FADD]] • [[Caspase-8]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">主要药剂</td><br />
<td style="padding: 10px 15px; color: #334155;">[[英夫利昔单抗]] • [[依那西普]] • [[TNFR1选择性抗体]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心病理</td><br />
<td style="padding: 10px 15px; color: #334155;">[[TRAPS]] • [[脓毒症]] • [[类风湿关节炎]] • [[多发性硬化症]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166